Latest Breaking News On - Apellis pharmaceuticals stock down - Page 1 : vimarsana.com

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q2 2024 Earnings of ($0.42) Per Share, Wedbush Forecasts

Needham & Company LLC Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results

UBS Group Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $85.00

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.5% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

Jennison Associates LLC Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Jennison Associates LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC’s holdings in Apellis Pharmaceuticals were worth $196,097,000 at the end of […]

Jennison Associates LLC Has $196.10 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Jennison Associates LLC lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC owned 2.76% of Apellis Pharmaceuticals […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 10,590,000 shares, a growth of 5.3% from the February 29th total of 10,060,000 shares. Based on an average trading volume of 1,580,000 shares, […]

Timothy Eugene Sullivan Sells 4,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the completion of the sale, the chief financial officer now […]

Apellis Pharmaceuticals' (APLS) "Neutral" Rating Reaffirmed at Mizuho